OncologyJohnson & Johnson
Johnson & Johnson Reports Phase 3 MARIPOSA Results for Rybrevant Plus Lazertinib in NSCLC
BMI
Biotechnology Media Insights
Editorial Team · October 15, 2023
J&J announces Phase 3 MARIPOSA trial results showing amivantamab plus lazertinib significantly improves progression-free survival vs osimertinib in EGFR-mutated NSCLC.
Johnson & Johnson today announced results from the Phase 3 MARIPOSA trial evaluating Rybrevant (amivantamab) plus lazertinib versus osimertinib as first-line treatment for EGFR-mutated non-small cell lung cancer. The trial met its primary endpoint, demonstrating a significant improvement in progression-free survival with the combination.
BMI
Biotechnology Media Insights
Published by Biotechnology Media Insights — your trusted source for pharmaceutical, biotech, and life sciences news.